{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T01:03:17Z","timestamp":1789779797275,"version":"4.0.1"},"reference-count":30,"publisher":"S. Karger AG","issue":"6","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncology"],"published-print":{"date-parts":[[2021]]},"abstract":"<jats:p>&lt;b&gt;&lt;i&gt;Background:&lt;\/i&gt;&lt;\/b&gt; Biliary tract cancer (BTC) is associated with poor prognosis because of its aggressive and heterogeneous nature. Programmed death ligand 1 (PD-L1) has been considered a novel biomarker for prognosis and response of immune checkpoint inhibitors in various tumors. However, there are limited data reporting on the role of PD-L1 in advanced BTC patients. &lt;b&gt;&lt;i&gt;Patients and Methods:&lt;\/i&gt;&lt;\/b&gt; We analyzed 186 patients with advanced BTC who received palliative gemcitabine and platinum between May 2010 and December 2019. All patients were evaluated for PD-L1 expression by combined positive score positivity. &lt;b&gt;&lt;i&gt;Results:&lt;\/i&gt;&lt;\/b&gt; Of the 186 patients, the primary tumor location was intrahepatic cholangiocarcinoma (IHCC) in 72 (38.7%), extrahepatic cholangiocarcinoma (EHCC) in 90 (48.4%), and gallbladder (GB) cancer in 24 (12.9%). Among all the patients, 53 (28.5%) had PD-L1 positivity. The median overall survival (OS) of patients with PD-L1 positivity or negativity was 12.1 and 15.4 months, respectively. The median progression-free survival (PFS) in patients with PD-L1 positivity or negativity was 5.7 and 7.1 months, respectively. OS and PFS were not statistically different between groups. In subgroup analysis, EHCC patients with PD-L1 negativity had more favorable OS (17.2 vs. 11.6 months, &lt;i&gt;p&lt;\/i&gt; = 0.002) and PFS (7.8 vs. 5.4 months, &lt;i&gt;p&lt;\/i&gt; = 0.005) than those who were PD-L1-positive. However, this finding was not reproduced in patients with IHCC or GB cancer. &lt;b&gt;&lt;i&gt;Conclusion:&lt;\/i&gt;&lt;\/b&gt; This study demonstrated that PD-L1 expression might be a novel prognostic biomarker in patients with EHCC but not in patients with IHCC or GB cancer. <\/jats:p>","DOI":"10.1159\/000514404","type":"journal-article","created":{"date-parts":[[2021,3,29]],"date-time":"2021-03-29T21:08:18Z","timestamp":1617052098000},"page":"365-372","source":"Crossref","is-referenced-by-count":11,"title":["Programmed Death Ligand 1 Expression as a Prognostic Marker in Patients with Advanced Biliary Tract Cancer"],"prefix":"10.1159","volume":"99","author":[{"given":"Hyera","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinchul","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seonggyu","family":"Byeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kee-Taek","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Yong","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeeyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se Hoon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joon Oh","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Suk","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho Yeong","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Ki","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Tae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2021,3,17]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.9-1-43"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0b013e3182708b57"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000000827"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097\/01.sla.0000251366.62632.d3"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds077"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-010-1325-4"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501824"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709684"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.9901"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.36"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.07.024"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1507"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0116-x"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2010.03.014"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1514296"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-016-5101-y"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-019-07701-4"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00897"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.7150\/thno.36276"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24351"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.3795"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5391-0"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1510353#SA1"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2019.37.15_suppl.4079"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020177"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1126\/science.1129139"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.30.5037"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1038\/nm730"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.610"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1002\/jso.21376"}],"container-title":["Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/514404","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/514404","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T16:24:06Z","timestamp":1745425446000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000514404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":30,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,5,27]]},"published-print":{"date-parts":[[2021,6,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000514404","archive":["Portico"],"relation":{},"ISSN":["0030-2414","1423-0232"],"issn-type":[{"value":"0030-2414","type":"print"},{"value":"1423-0232","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021]]}}}